Barclays
ARTV

Barclays’s Artiva Biotherapeutics ARTV Stock Holding History

Barclays’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,696
Closed -$36.4K – 5789
2025
Q3 		$36.4K Buy
12,696
+10,790
+566% +$28.9K ﹤0.01% 4845
2025
Q2 		$2.88K Sell
1,906
-20,847
-92% -$43.8K ﹤0.01% 5013
2025
Q1 		$68.3K Sell
22,753
-1,408
-6% -$7.6K ﹤0.01% 4526
2024
Q4 		$244K Buy
24,161
+4,545
+23% +$54.6K ﹤0.01% 4216
2024
Q3 		$303K Buy
+19,616
New +$227K ﹤0.01% 4084

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Barclays's ARTV Position: Q4 2025 in Review

Barclays sold out of Artiva Biotherapeutics (ARTV) in Q4 2025, closing a stake of 12,696 shares — an estimated $36.4K sold.

Barclays first reported a position in ARTV in Q3 2024 and held it in 5 quarters. The position peaked at $303K in Q3 2024. 34 funds tracked by Wall St. Rank hold ARTV as of Q4 2025.

  • Barclays reported no remaining Artiva Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Barclays sold 12,696 Artiva Biotherapeutics shares in Q4 2025, an estimated $36.4K.
  • Barclays first reported a position in Artiva Biotherapeutics in Q3 2024 and held it in 5 quarters.
  • Barclays's Artiva Biotherapeutics position peaked at $303K in Q3 2024.
  • 34 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.